Ajinomoto Bio-Pharma Services vs Novartis: CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Novartis?
As of Oct 2026, Ajinomoto Bio-Pharma Services: no FDA inspections on file, 1 EMA/MHRA GMP certificate. Signal Score 83.5. Novartis: 17 FDA inspections (including 9 NAI, 8 VAI and 0 OAI), 51 EMA/MHRA GMP certificates. Signal Score 85.4. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (17 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Novartis holds 50 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
Across the cross-modality scorecard, Novartis carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Ajinomoto Bio-Pharma Services vs Novartis
How does Ajinomoto Bio-Pharma Services compare to Novartis?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and Novartis is 85/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 17 for Novartis; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 51 for Novartis. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Novartis?
Both Ajinomoto Bio-Pharma Services and Novartis maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Novartis has 17.
How do Ajinomoto Bio-Pharma Services and Novartis compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Novartis holds 50 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or Novartis?
Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 84/100 and Novartis carries 85/100 — essentially tied for Novartis. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →